Ownership Don’t Lie: Escalon Medical Corp (OTCMKTS:ESMC) Sentiment Increased, Because Downtrend

November 21, 2016 - By Hazel Jackson   ·   0 Comments

Ownership Don't Lie: Escalon Medical Corp (OTCMKTS:ESMC) Sentiment  Increased,  Because Downtrend

Sentiment for Escalon Medical Corp (OTCMKTS:ESMC)

Escalon Medical Corp (OTCMKTS:ESMC) institutional sentiment increased to 8 in Q2 2016. Its up 6.67, from 1.33 in 2016Q1. The ratio has improved, as 4 institutional investors opened new or increased equity positions, while 3 sold and reduced stakes in Escalon Medical Corp. The institutional investors in our partner’s database reported: 1.39 million shares, up from 1.30 million shares in 2016Q1. Also, the number of institutional investors holding Escalon Medical Corp in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 2 Increased: 3 New Position: 1.

Escalon Medical Corp. operates in the healthcare market. The company has a market cap of $839,629. The Firm is engaged in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. It currently has negative earnings. The Company’s A-Scan provides information about the internal structure of the eye by sending a beam of ultrasound along a fixed axis through the eye and displaying the various echoes reflected from the surfaces intersected by the beam.

Escalon Medical Corp. (OTCMKTS:ESMC) has declined 65.33% since April 19, 2016 and is downtrending. It has underperformed by 69.19% the S&P500.

According to Zacks Investment Research, “Escalon Medical Corp. develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. The company utilizes strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the company’s distribution capabilities.”

Grt Capital Partners L.L.C. holds 0.12% of its portfolio in Escalon Medical Corp. for 601,736 shares. Bank Of New York Mellon Corp owns 16,000 shares or 0% of their US portfolio. Moreover, Blackrock Advisors Llc has 0% invested in the company for 1,399 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Blackrock Institutional Trust Company N.A., a California-based fund reported 271,235 shares.#img1#

ESMC Company Profile

Escalon Medical Corp., incorporated on September 27, 2001, operates in the healthcare market. The Firm is engaged in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company’s subsidiaries include Sonomed, Inc. (Sonomed), Trek, Inc. (Trek), Escalon Digital Solutions, Inc. (EMI), Escalon Holdings, Inc. (EHI), Escalon IP Holdings, Inc., Sonomed IP Holdings, Inc. and Drew Scientific Group, Plc (Drew).

More notable recent Escalon Medical Corp. (OTCMKTS:ESMC) news were published by: Prnewswire.com which released: “Escalon® Medical Corp. Reports Fiscal 2015 Results” on September 28, 2015, also Businesswire.com with their article: “ERBA Diagnostics, Inc. Acquires Escalon Medical Corp. Clinical Diagnostics …” published on October 04, 2012, Bizjournals.com published: “Medical device manufacturer to be delisted from NASDAQ on Friday” on November 17, 2016. More interesting news about Escalon Medical Corp. (OTCMKTS:ESMC) were released by: Bizjournals.com and their article: “Medical device firms gets delisting notice” published on February 24, 2016 as well as Prnewswire.com‘s news article titled: “Escalon® Medical Corp. to Introduce Sonomed Escalon VuPadâ„¢ at Annual Meeting …” with publication date: November 14, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>